FEops Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Employees
  • 36

Employees
  • Latest Deal Type
  • Grant

  • (Announced)
  • Latest Deal Amount
  • $500K

  • Investors
  • 9

FEops General Information

Description

Developer of a cardiac imaging technology designed to improve and expand personalized treatment for patients with structural heart disease. The company offers AI-enabled anatomical analyses to generate data-driven insights to improve transcatheter valve procedures based on personalized computer simulations, enabling healthcare professionals to improve both procedure efficiency and clinical outcomes.

Contact Information

Website
www.feops.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Other Healthcare Technology Systems
Primary Office
  • Technologiepark 122
  • 9052 Gent
  • Belgium
+32 09 000 00 00

FEops Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

FEops Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 01-Jul-2021 $500K 00.000 Announced Generating Revenue
8. Grant 30-Jun-2021 00000 00.000 Completed Generating Revenue
7. Grant 16-Apr-2020 00000 00.000 Completed Generating Revenue
6. Accelerator/Incubator 10-Dec-2019 00.00 00.000 Completed Generating Revenue
5. Accelerator/Incubator 23-Sep-2019 00.000 Completed Generating Revenue
4. Grant 12-Nov-2018 00.000 00.000 Completed Generating Revenue
3. Later Stage VC (Series B) 22-Sep-2017 00.000 00.000 Completed Generating Revenue
2. Grant 20-Jan-2016 $54.5K $1.68M Completed Generating Revenue
1. Early Stage VC (Series A) 19-Dec-2014 $1.68M $1.68M 00.000 Completed Generating Revenue
To view FEops’s complete valuation and funding history, request access »

FEops Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B 00,000 000.0 000.0 00 000.0 00.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Preference 4,845 $19.97 $19.97 1x $19.97 2.86%
To view FEops’s complete cap table history, request access »

FEops Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a cardiac imaging technology designed to improve and expand personalized treatment for patients with struct
Decision/Risk Analysis
Gent, Belgium
36 As of 2022
00.000
0000000000 00.000

0-0000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
00000 0000000000 0000000000 0000000
Sunnyvale, CA
00 As of 0000
00.000
000000&0 00.000

000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000000000000 00000000
London, United Kingdom
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

FEops Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
i-Human Patients Formerly Angel backed Sunnyvale, CA 00 00.000 000000&0 00.000
00000000 Venture Capital-Backed London, United Kingdom 000 00000 00000000000 00000
000000000 Venture Capital-Backed Santa Clara, CA 00 000.00 000000000 - 000.00
0000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
0-0000 0000000 Corporate Backed or Acquired Washington, DC 00 000000&0
You’re viewing 5 of 17 competitors. Get the full list »

FEops Patents

FEops Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3706137-A1 Method and system for patient-specific predicting of cyclic loading failure of a cardiac implant Pending 08-Mar-2019 000000000 0
JP-2021518235-A Methods and systems for patient-specific virtual percutaneous structural cardiac interventions Pending 23-Mar-2018 0000000000
EP-3542757-A1 Method and system for patient-specific virtual percutaneous structural heart intervention Withdrawn 23-Mar-2018 0000000000 0
EP-3768193-A1 Method and system for patient-specific virtual percutaneous structural heart intervention Pending 23-Mar-2018 000000000
US-20210022806-A1 Method and system for patient-specific virtual percutaneous structural heart intervention Pending 23-Mar-2018 A61F2/2415
To view FEops’s complete patent history, request access »

FEops Executive Team (7)

Name Title Board Seat Contact Info
Matthieu De Beule Ph.D Co-Founder, Chief Executive Officer & Board Member
Isabelle Decroos Chief Financial Officer
Peter Mortier Ph.D Co-Founder, Chief Technology Officer, Board Member and Managing Director
Nico Uwents Director, Business Development
Christian Vincent Director, Therapy Development
You’re viewing 5 of 7 executive team members. Get the full list »

FEops Board Members (9)

Name Representing Role Since
Euan Thomson Ph.D Self Board Member 000 0000
Jose Gordo Self Board Member 000 0000
Kenneth Wils PMV Board Member 000 0000
Marc Lambrechts Ph.D Capricorn Partners Board Member 000 0000
Matthieu De Beule Ph.D FEops Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

FEops Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FEops Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Vlaams Agentschap Innoveren en Ondernemen Endowment Limited Partner 000 0000 000000 0
European Commission Government 000 0000 000000 0
3DEXPERIENCE Lab Accelerator/Incubator Minority 000 0000 000000 0
ITEA 3 Corporation 000 0000 000000 0
Personalised In-silico Cardiology Corporation 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »